Goldman Sachs
BIOA

Goldman Sachs’s BioAge Labs BIOA Stock Holding History

Goldman Sachs’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.64M Buy
270,769
+114,331
+73% +$2.07M ﹤0.01% 3627
2026
Q1 		$2.74M Buy
156,438
+30,200
+24% +$582K ﹤0.01% 4251
2025
Q4 		$1.67M Buy
126,238
+36,560
+41% +$324K ﹤0.01% 4750
2025
Q3 		$527K Buy
89,678
+64,886
+262% +$304K ﹤0.01% 5480
2025
Q2 		$102K Sell
24,792
-1,967
-7% -$7.92K ﹤0.01% 5810
2025
Q1 		$101K Sell
26,759
-169,208
-86% -$782K ﹤0.01% 5784
2024
Q4 		$1.13M Buy
195,967
+87,351
+80% +$1.51M ﹤0.01% 4735
2024
Q3 		$2.26M Buy
+108,616
New +$2.18M ﹤0.01% 4055

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Goldman Sachs's BIOA Position: Q2 2026 in Review

Goldman Sachs increased its BioAge Labs (BIOA) stake by 73% in Q2 2026, buying an estimated $2.07M and bringing the position to 270,769 shares worth $6.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3627.

Goldman Sachs first reported a position in BIOA in Q3 2024 and has held it in 8 quarters since. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Goldman Sachs held 270,769 shares of BioAge Labs worth $6.64M as of Q2 2026.
  • Goldman Sachs bought 114,331 BioAge Labs shares in Q2 2026, an estimated $2.07M.
  • BioAge Labs made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3627 holding.
  • Goldman Sachs first reported a position in BioAge Labs in Q3 2024 and has held it in 8 quarters since.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.